|
|Section2= |Section3= }} Mafosfamide (INN) is an oxazaphosphorine (cyclophosphamide-like) alkylating agent under investigation as a chemotherapeutic. It is metabolized by cytochrome P450 into 4-Hydroxycyclophosphamide, which is then converted into aldophosphamide, which, in turn yields the cytotoxic metabolites phosphoramide mustard and acrolein.〔 Ludeman SM. The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des. 1999 Aug;5(8):627-43. PMID 10469895〕 Several Phase I trials have been completed.〔 ClinicalTrials.gov Identifier NCT00062881.〕〔 ClinicalTrials.gov Identifier NCT00031928.〕 ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Mafosfamide」の詳細全文を読む スポンサード リンク
|